Safety and Efficacy of NAFT900 in Children With Tinea Capitis
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Double-Blind, Randomized, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy
and Safety of NAFT-900 in Children Aged 6 to < 13 Years with Tinea Capitis
Phase:
Phase 2
Details
Lead Sponsor:
Merz North America, Inc. Merz Pharmaceuticals, LLC